There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Intercept Pharma (NASDAQ:ICPT) and Irhythm Technologies (NASDAQ:IRTC) with bullish sentiments.
Intercept Pharma (ICPT)
In a report released yesterday, Brian Abrahams from RBC Capital reiterated a Buy rating on Intercept Pharma, with a price target of $115. The company’s shares closed yesterday at $100.83.
According to TipRanks.com, Abrahams is a 5-star analyst with an average return of 12.2% and a 55.8% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Proteostasis Therapeutics Inc, Intra-Cellular Therapies, and Alder Biopharmaceuticals.
Intercept Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $121.67, representing a 20.7% upside. In a report issued on July 24, Cowen & Co. also assigned a Buy rating to the stock with a $88 price target.
.
See today’s analyst top recommended stocks >>
Irhythm Technologies (IRTC)
In a report released yesterday, Glenn Novarro from RBC Capital reiterated a Buy rating on Irhythm Technologies, with a price target of $93. The company’s shares closed yesterday at $85.04, close to its 52-week high of $90.40.
According to TipRanks.com, Novarro is a 5-star analyst with an average return of 14.7% and a 79.5% success rate. Novarro covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Baxter International, and Edwards Lifesciences.
Currently, the analyst consensus on Irhythm Technologies is a Moderate Buy with an average price target of $88.40, representing a 4.0% upside. In a report issued on August 1, BMO Capital also reiterated a Buy rating on the stock with a $96 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
